keyboard_arrow_up

Inflammatory Bowel Disease Pipeline and Market Review, H1 2015

This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. Get a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=403526 . (This is a premium report price at US$2000 for a single user PDF license)

Some of the Company profiles mentioned in this report are Ampio Pharmaceuticals, Apogee Biotechnology Corporation, Argos Therapeutics, Biotec Pharmacon ASA, Bristol-Myers Squibb Company, Catabasis Pharmaceuticals, Cosmo Pharmaceuticals S.p.A, Delenex Therapeutics AG, Epirus Biopharmaceuticals, Immune Response BioPharma, Inc., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Omni Bio Pharmaceutical Inc., Opsona Therapeutics Limited, RedHill Biopharma Ltd.

Scope

- The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.